BACKGROUND: Little is known about the use of warfarin in hemodialysis (HD) patients with atrial fibrillation (AF). We studied temporal trends of AF among older HD patients, and of warfarin use among those with AF. METHODS: We linked US Medicare and prescription claims from older patients undergoing HD in 2 Eastern US states. We established annual cohorts of prevalent HD patients; AF was ascertained from >2 claims (>7 days apart) in the same year, with a diagnosis code indicating AF. Among those with AF, we defined current and past warfarin use. Demographic and clinical characteristics were also ascertained for each cohort. We used repeated-measures logistic regression to define the odds of AF and of current or past versus absence of warfarin use. RESULTS: Of 6,563 unique patients, 2,185 were determined to have AF. The prevalence of AF increased from 26% in 1998 to 32% in 2005. In 2005, current warfarin use was present in 24% of AF patients and past use in 25%; 51% had no evidence of any warfarin use. No significant trends in utilization were observed from 1998 through 2005. Patients aged =85 years and nonwhites were less likely to have received warfarin; most comorbidities were not associated with warfarin use except for patients with past pulmonary embolism or deep venous thrombosis who were more likely than those without such history. CONCLUSION: While the prevalence of AF has been increasing among older HD patients, warfarin use was low and unchanged over time, perhaps reflecting the lack of evidence supporting its use.
BACKGROUND: Little is known about the use of warfarin in hemodialysis (HD) patients with atrial fibrillation (AF). We studied temporal trends of AF among older HDpatients, and of warfarin use among those with AF. METHODS: We linked US Medicare and prescription claims from older patients undergoing HD in 2 Eastern US states. We established annual cohorts of prevalent HDpatients; AF was ascertained from >2 claims (>7 days apart) in the same year, with a diagnosis code indicating AF. Among those with AF, we defined current and past warfarin use. Demographic and clinical characteristics were also ascertained for each cohort. We used repeated-measures logistic regression to define the odds of AF and of current or past versus absence of warfarin use. RESULTS: Of 6,563 unique patients, 2,185 were determined to have AF. The prevalence of AF increased from 26% in 1998 to 32% in 2005. In 2005, current warfarin use was present in 24% of AFpatients and past use in 25%; 51% had no evidence of any warfarin use. No significant trends in utilization were observed from 1998 through 2005. Patients aged =85 years and nonwhites were less likely to have received warfarin; most comorbidities were not associated with warfarin use except for patients with past pulmonary embolism or deep venous thrombosis who were more likely than those without such history. CONCLUSION: While the prevalence of AF has been increasing among older HDpatients, warfarin use was low and unchanged over time, perhaps reflecting the lack of evidence supporting its use.
Authors: Kamakshi Lakshminarayan; Craig A Solid; Allan J Collins; David C Anderson; Charles A Herzog Journal: Stroke Date: 2006-06-29 Impact factor: 7.914
Authors: Niteesh K Choudhry; Geoffrey M Anderson; Andreas Laupacis; Dennis Ross-Degnan; Sharon-Lise T Normand; Stephen B Soumerai Journal: BMJ Date: 2006-01-10
Authors: Stephen L Seliger; Daniel L Gillen; W T Longstreth; Bryan Kestenbaum; Catherine O Stehman-Breen Journal: Kidney Int Date: 2003-08 Impact factor: 10.612
Authors: Haimanot Wasse; Daniel L Gillen; Adrianne M Ball; Bryan R Kestenbaum; Stephen L Seliger; Donald Sherrard; Catherine O Stehman-Breen Journal: Kidney Int Date: 2003-10 Impact factor: 10.612
Authors: Eduardo Vázquez; Carmen Sánchez-Perales; M-José García-Cortes; Francisco Borrego; Cristóbal Lozano; Manuel Guzmán; José Manuel Gil; Antonio Liébana; Pilar Pérez; M-José Borrego; Vicente Pérez Journal: Int J Cardiol Date: 2003-02 Impact factor: 4.164
Authors: Jenny I Shen; Maria E Montez-Rath; Colin R Lenihan; Mintu P Turakhia; Tara I Chang; Wolfgang C Winkelmayer Journal: Am J Kidney Dis Date: 2015-07-07 Impact factor: 8.860
Authors: Giuseppe Boriani; Irina Savelieva; Gheorghe-Andrei Dan; Jean Claude Deharo; Charles Ferro; Carsten W Israel; Deirdre A Lane; Gaetano La Manna; Joseph Morton; Angel Moya Mitjans; Marc A Vos; Mintu P Turakhia; Gregory Y H Lip Journal: Europace Date: 2015-06-24 Impact factor: 5.214